Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Methylprednisolone (Primary) ; Ublituximab (Primary)
- Indications Neuromyelitis optica; Optic neuritis
- Focus Adverse reactions; Proof of concept
- Sponsors TG Therapeutics Inc
- 14 Mar 2018 Planned End Date changed from 28 Feb 2018 to 28 Jul 2018.
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 28 Feb 2018.
- 20 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History